Recently, with the advancement of research on the pathophysiology of DLBCL, many biological and molecular features, such as the cell of origin (COO), BCL2 and MYC status, and genetic alteration, have been discovered to be associated with poor prognosis (8–13). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.